Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for VitektaTM tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
http://www.businesswire.com/news/topix/20131118005601/en
http://www.businesswire.com/news/topix/20131118005601/en
No comments:
Post a Comment